X0609 4 2026-06-11 0001628171 Revolution Medicines, Inc. RVMD 0001294192 Horn Margaret A false C/O REVOLUTION MEDICINES, INC. 700 SAGINAW DRIVE REDWOOD CITY CA 94063 true Chief Operating Officer true Common Stock 2026-06-11 4 M 0 1094 42.45 A 159316 D Common Stock 2026-06-11 4 M 0 8906 40.74 A 168222 D Common Stock 2026-06-11 4 S 0 1315 144.2793 D 166907 D Common Stock 2026-06-11 4 S 0 885 145.1495 D 166022 D Common Stock 2026-06-11 4 S 0 700 146.0371 D 165322 D Common Stock 2026-06-11 4 S 0 500 147.272 D 164822 D Common Stock 2026-06-11 4 S 0 1800 148.7231 D 163022 D Common Stock 2026-06-11 4 S 0 4600 149.6429 D 158422 D Common Stock 2026-06-11 4 S 0 200 150.17 D 158222 D Stock Option (Right to Buy) 42.45 2026-06-11 4 M 0 1094 0 D 2023-08-09 2031-03-03 Common Stock 1094 0 D Stock Option (Right to Buy) 40.74 2026-06-11 4 M 0 8906 0 D 2035-02-28 Common Stock 8906 91194 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. Includes 73,050 restricted stock units. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026. This transaction was executed in multiple trades in prices ranging from $143.78 to $144.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $144.79 to $145.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $145.88 to $146.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $147.06 to $147.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $148.14 to $149.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $149.17 to $150.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. /s/ Jack Anders, as Attorney-in-fact for Margaret Horn 2026-06-15